Answers are grounded in this paper and cite their sources.
Case study demonstrates Ankaferd Blood Stopper’s effectiveness for wound healing in a patient with burns and cancer, suggesting significant clinical benefit.
Ankaferd Blood Stopper (ABS; Imumm Gida Ilaç Kozmetic San. ve.Tic. Ltd., Turkey) is a unique blend of traditional medicinal plant extracts historically used in Turkish folk medicine as a haemostatic agent. In addition, it has antimicrobial and wound healing properties. This case study describes the treatment of a patient with a burn injury lasting >2 months. During the healing process, the patient was evaluated for suspected malignancy and was diagnosed with pancreatic cancer. Under these new circumstances, the decision was made, with the patient's consent, to try ABS with the aim of optimising the patient's metabolic and physical conditions before starting cancer treatment. Complete wound closure was achieved 18 days after the start of treatment, after only 14 days of ABS treatment. It is therefore concluded that the use of ABS was beneficial, allowing complete wound closure prior to the start of chemotherapy and subsequent surgery, in the patient who had characteristics that made healing difficult.
No takes yet. Share an insight, caveat, or question.
Pilar Palomares Díaz (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: